Suppr超能文献

采用光场技术的质子束辐照治疗脉络膜血管瘤。

Proton beam irradiation using a light-field technique for the treatment of choroidal hemangiomas.

机构信息

Retina Service, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA.

出版信息

Ophthalmologica. 2010;224(4):209-16. doi: 10.1159/000260226. Epub 2009 Nov 24.

Abstract

BACKGROUND/AIMS: To describe the clinical outcomes of patients with circumscribed and diffuse choroidal hemangiomas treated by proton beam irradiation using a nonsurgical light-field technique.

METHODS

A retrospective chart review was performed on a series of 19 patients (19 eyes) with choroidal hemangiomas treated with proton beam therapy between July 1988 and August 2005. Choroidal hemangiomas were treated with proton beam irradiation using a light-field technique and doses ranging from 15 to 30 cobalt Gray equivalents (CGE; CGE = proton Gy x relative biological effectiveness 1.1) in 4 fractions. Patients with at least 6 months' follow-up were included in the study. Tumor regression, visual acuity, absorption of subretinal fluid, and treatment-associated complications were evaluated by clinical examination and ultrasonography.

RESULTS

Visual acuity improved or remained stable in 14 of 18 eyes (78%). Subretinal fluid was initially present in 16 of 19 eyes (84%), and completely resolved in all 16 eyes. Tumor height, as measured by B-scan ultrasonography, decreased in 18 of 19 eyes and remained stable in 1 of 19, as of the last examination. Complications of radiation developed in 9 of 19 eyes (47%) with the total applied dose ranging from 15 to 30 CGE for these 9 eyes.

CONCLUSIONS

Proton beam irradiation using a light-field technique without surgical tumor localization is an effective treatment option in managing both circumscribed choroidal hemangiomas and diffuse hemangiomas associated with Sturge-Weber syndrome. A total proton dose as low as 15 CGE applied in 4 fractions appears to be sufficient to reduce tumor size, promote absorption of subretinal fluid, and improve or stabilize vision in most patients.

摘要

背景/目的:描述采用非手术光场技术的质子束照射治疗局限性和弥漫性脉络膜血管瘤患者的临床结果。

方法

对 1988 年 7 月至 2005 年 8 月期间采用质子束疗法治疗的 19 例(19 只眼)脉络膜血管瘤患者的系列病例进行回顾性图表审查。采用光场技术,对脉络膜血管瘤进行质子束照射治疗,剂量范围为 15 至 30 钴格雷当量(CGE;CGE = 质子 Gy x 相对生物学效应 1.1),共 4 个分次。纳入研究的患者均具有至少 6 个月的随访。通过临床检查和超声检查评估肿瘤消退、视力、视网膜下液吸收以及与治疗相关的并发症。

结果

18 只眼中 14 只(78%)视力提高或保持稳定。19 只眼中 16 只(84%)最初存在视网膜下液,所有 16 只眼均完全吸收。B 型超声测量的肿瘤高度在 19 只眼中 18 只眼下降,19 只眼中 1 只眼稳定,为最后一次检查。9 只眼(47%)发生了与总应用剂量为 15 至 30 CGE 的辐射相关的并发症。

结论

采用光场技术而不进行手术肿瘤定位的质子束照射是治疗局限性脉络膜血管瘤和与 Sturge-Weber 综合征相关的弥漫性血管瘤的有效治疗选择。在大多数患者中,4 个分次应用低至 15 CGE 的总质子剂量似乎足以减小肿瘤大小、促进视网膜下液吸收并改善或稳定视力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验